valganciclovir bluepharma 450 mg comprimido revestido por película
bluepharma genéricos - comércio de medicamentos s.a. - valganciclovir - comprimido revestido por película - 450 mg - valganciclovir, cloridrato 496.3 mg - valganciclovir - genérico - duração do tratamento: longa duração
sunitinib bluepharma 12.5 mg cápsula
bluepharma genéricos - comércio de medicamentos s.a. - sunitinib - cápsula - 12.5 mg - cloridrato de sunitinib 13.646 mg - sunitinib - genérico - duração do tratamento: longa duração
sunitinib bluepharma 37.5 mg cápsula
bluepharma genéricos - comércio de medicamentos s.a. - sunitinib - cápsula - 37.5 mg - cloridrato de sunitinib 40.939 mg - sunitinib - genérico - duração do tratamento: longa duração
duloxetina eignapharma 30 mg cápsula gastrorresistente
eignapharma, s.l. - duloxetina - cápsula gastrorresistente - 30 mg - duloxetina, cloridrato 33.65 mg - duloxetine - genérico - duração do tratamento: longa duração
amoxicilina netpharmalab 500 mg cápsula
netpharmalab consulting services s.l. - amoxicilina - cápsula - 500 mg - amoxicilina tri-hidratada 574 mg - amoxicillin - genérico - duração do tratamento: curta ou média duração
amoxicilina netpharmalab 500 mg cápsula
netpharmalab consulting services s.l. - amoxicilina - cápsula - 500 mg - amoxicilina tri-hidratada 574 mg - amoxicillin - genérico - duração do tratamento: curta ou média duração
duloxetina eignapharma 60 mg cápsula gastrorresistente
eignapharma, s.l. - duloxetina - cápsula gastrorresistente - 60 mg - duloxetina, cloridrato 67.3 mg - duloxetine - genérico - duração do tratamento: longa duração
amoxicilina netpharmalab 250 mg pó para suspensão oral
netpharmalab consulting services s.l. - amoxicilina - pó para suspensão oral - 250 mg - amoxicilina tri-hidratada 295.59 mg - amoxicillin - genérico - duração do tratamento: curta ou média duração
budesonide/formoterol teva pharma b.v.
teva pharma b.v. - budesonide, formoterol - asma - medicamentos para obstrutiva, doenças das vias respiratórias, - budesonide / formoterol teva pharma b. é indicado em adultos de 18 anos ou mais apenas. asthmabudesonide/formoterol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - cloridrato de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agentes antitrombóticos - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.